Bir Plassi Near Sainimajraropar,
Nalagarh Road
District Solan – 174101,
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/
Last updated on 18-Nov-2024 18:43:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 912000 | 29634000 | 32.49 |
| NIB | 688000 | 415166000 | 603.44 |
| RETAIL | 1600000 | 190978000 | 119.36 |
| Total | 3200000 | 635778000 | 198.68 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 22 |
| NIB | 9351 |
| RETAIL | 95489 |
| Total | 104862 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 5.56 | 180.77 | 32.49 |
| NIB | 4.2 | 2532.51 | 603.44 |
| RETAIL | 9.76 | 1164.97 | 119.36 |
| Total | 19.52 | 3878.25 | 198.68 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹2.66 | @8% ₹3.04 | @9% ₹3.42 | @10% ₹3.8 | @11% ₹4.18 | @12% ₹4.56 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹49.42 | @8% ₹56.48 | @9% ₹63.53 | @10% ₹70.59 | @11% ₹77.65 | @12% ₹84.71 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 2000 | 122000 | 800 |
| HNI | 2 | 4000 | 244000 | 344 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 33.26% | 1600000 |
| NII (HNI) | 14.30% | 688000 |
| Anchor | 28.40% | 1366000 |
| QIB | 18.96% | 912000 |
| Market Maker | 5.07% | 244000 |
| Total | 100.00% | 4810000 |
Onyx Biotec IPO Details
| Issue Size | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Fresh Issue | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 13,322,200 |
| Share holding post issue | 18,132,200 |
| Market Maker portion | 244,000 shares |
| Market Maker | Giriraj Stock Broking |
Key Performance Indicator
| KPI | May-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 4.99% | 12.19% | 10.13% |
| ROCE | 3.71% | 10.58% | 6.29% |
| RONW | 4.99% | 12.19% | 10.13% |
| EPS (basic) | 0.98 | 2.54 | 1.56 |
| P/E Pre IPO | 26.81 | ||
| P/E Post IPO | 14.1 |
Company Financials
Onyx Biotec Limited Financial Information (Restated) In Lakhs.
| Period | May 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Assets | 7,476.5 | 7,413.5 | 5,872.3 | 3,683.8 |
| Revenue | 1,054.1 | 5,387.4 | 3,961.6 | 4,498.0 |
| Profit | 130.7 | 303.1 | 184.4 | 335.2 |
| Net Worth | 2,618.6 | 2,487.8 | 1,820.1 | 1,637.5 |
| Reserves | 1,286.4 | 1,155.6 | 1,230.0 | 1,047.4 |
| Borrowing | 3,156.1 | 3,078.0 | 2,922.8 | 1,224.3 |
| Amount in ₹ Lakhs | ||||
About Company
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company specializing in sterile water for injections and contract manufacturing of pharmaceutical products. The company operates two manufacturing units in Solan, Himachal Pradesh, with Unit I producing up to 638,889 units of sterile water injections daily and Unit II manufacturing 40,000 units of dry powder injections and 26,667 units of dry syrup per day. Serving both Indian and international markets, Onyx Biotec has built a diverse clientele, including major pharmaceutical names like Hetero Healthcare, Mankind Pharma, Sun Pharma, and Reliance Life Sciences, among over 100 clients as of May 31, 2024. The company is ISO 9001:2015 and ISO 14001:2015 certified, emphasizing quality and environmental management standards, and employs 175 people as of July 31, 2024.
Strength
Expertise in Sterile Manufacturing: A leading contract manufacturer specializing in sterile products, ensuring high standards in production.
Quality Assurance and Control: Emphasis on rigorous quality assurance and control processes to maintain product safety and effectiveness.
Established Client Relationships: Long-term, strong relationships with a prestigious client base, reinforcing trust and repeat business.
Weakness
Regional Concentration Risk: With all manufacturing units located in Solan, Himachal Pradesh, the company is vulnerable to regional economic, political, and natural disaster risks, which could disrupt operations.
Operational Disruptions: Any slowdown or shutdown in manufacturing could significantly impact business performance, financial condition, and cash flows.
Quality and Delivery Risks: Issues in manufacturing or quality control, or delays in product delivery, could lead to canceled orders, breached agreements, and loss of client trust, adversely affecting financial stability.